No delay in entering into purchase pacts with domestic COVID-19 vaccine manufacturers: Govt

On the quantum of funds spent on the vaccination programme, she said Rs 9,725.15 crore have so far been spent on it, including for procurement of vaccines and the operational cost for vaccination.

PTI
July 23, 2021 / 03:02 PM IST

There has been no delay in entering into purchase agreements with domestic Covid vaccine manufacturers and advance payments have also been made for the supply orders placed with them, the government informed Parliament on Friday.

In a written reply to a question in the Lok Sabha from Congress member Rahul Gandhi and TMC's Mala Roy, Minister of State for Health Bharati Pravin Pawar said a total of 135 crore COVID-19 vaccine doses are expected to be available between August and December, and though no fixed timeline can be indicated for the completion of the vaccination drive, it is expected that all beneficiaries aged 18 years and above will be inoculated by December.

On the quantum of funds spent on the vaccination programme, she said Rs 9,725.15 crore have so far been spent on it, including for procurement of vaccines and the operational cost for vaccination.

On whether the government proposes to complete the exercise of full Covid vaccination of all adults by the end of the year, Pawar said it is an ongoing and dynamic process, which is being guided by the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) on the basis of concurrent scientific evidence.

"In view of the dynamic and evolving nature of the COVID-19 pandemic, no fixed timeline at present can be indicated for the completion of the vaccination drive, however, it is expected that beneficiaries aged 18 years and above will be vaccinated by December 2021," she said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
On whether the government has taken note of a significant delay in entering into advance purchase agreements with vaccine manufacturers, thereby adversely affecting the pace of the vaccine rollout, the minister said, "There has been no delay in entering into purchase agreements with the domestic vaccine manufacturers. Advance payments have also been made to the manufacturers for the supply orders placed with them."
PTI
Tags: #coronavirus #Covid-19 #Current Affairs #India #vaccine
first published: Jul 23, 2021 03:03 pm